Sign in Subscribe
Cancer research

Breakthrough in Breast Cancer Treatment: New Nanoparticle Formulation Shows Promising Results

Strategic Insights

— 1 min read

Scientists at the Institute of Medicinal Plant Development have developed a novel nanoparticle-based approach to enhance chemoimmunotherapy against 4T1 breast cancer. The research, funded by the Chinese Academy of Medical Sciences Initiative For Innovative Medicine, presents a significant advancement in cancer therapy. The new formulation, which combines squamocin with MnO2 nanoparticles, has demonstrated a synergistic anti-tumor effect, achieving a tumor inhibition rate of approximately 92%.

Key Takeaways:

  • The Institute of Medicinal Plant Development has developed a novel chemoimmunotherapy approach using MnO2 nanoparticles combined with squamocin, which has shown substantial promise in enhancing anti-tumor efficacy.
  • Squamocin, a naturally derived compound, exhibits potent anti-tumor activity but is limited by poor water solubility and off-target toxicity.
  • The MnO2 nanoparticle formulation was synthesized from KMnO4 and anhydrous ethanol, and modified with Astragalus polysaccharides (APS)-IR820 to improve stability and facilitate tumor targeting.
  • The nanoparticles (193.4 ± 1.7 nm in size) generated Mn2+ in response to GSH levels within the tumor microenvironment, inducing maturation of bone marrow dendritic cells and repolarization of tumor-associated macrophages.
  • The chemoimmunotherapy approach, combined with Squ@APS-IR820 NPs (220.1 ± 11.2 nm in size), stimulated both innate and adaptive immune responses in a 4T1 tumor-bearing mouse model and achieved a tumor inhibition rate of approximately 92%.
  • The research highlights the potential of the MnO2-based tumor-seeking nanoplatform for enhanced chemoimmunotherapy against breast cancer.

Statistics:

  • The MnO2 nanoparticle formulation was 193.4 ± 1.7 nm in size, while the Squ@APS-IR820 NPs were 220.1 ± 11.2 nm in size.
  • The generated Mn2+ induced a maturation of bone marrow dendritic cells, promoting repolarization of tumor-associated macrophages from the M2 to the M1 phenotype.
  • The chemoimmunotherapy approach achieved a tumor inhibition rate of approximately 92% in a 4T1 tumor-bearing mouse model.

Sources:

  • A MnO2-based tumor-seeking nanoplatform for enhanced chemoimmunotherapy against 4T1 breast cancer. Materials Today Bio, 2025,33():102000.
  • Published by Elsevier.
  • https://doi-org.sdpl.idm.oclc.org/10.1016/j.mtbio.2025.102000

Read more